Polyclonal Antibody to Cyclin Dependent Kinase Inhibitor 2A (CDKN2A)
| Code | Size | Price |
|---|
| PAA794Mu01-20ul | 20ul | £82.00 |
Quantity:
| PAA794Mu01-100ul | 100ul | £152.00 |
Quantity:
| PAA794Mu01-200ul | 200ul | £204.00 |
Quantity:
| PAA794Mu01-1ml | 1ml | £464.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Mouse
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
P16; ARF; CDK4I; CMM2; INK4; INK4a; MLM; MTS1; TP16; P14; P14ARF; P16INK4a; P19; Melanoma P16; Cyclin-dependent kinase 4 inhibitor A; Multiple tumor suppressor 1
Buffer Formulation:
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Item Name:
Cyclin Dependent Kinase Inhibitor 2A
Reactivity:
Po;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.01-2ug/mL;<br/>Immunohistochemistry: 5-20ug/mL;<br/>Immunocytochemistry: 5-20ug/mL;<br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Cyclin Dependent Kinase Inhibitor 2A (CDKN2A) | RPA794Mu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||